Weight Watchers Med+ to Support Medicare Members Seeking GLP-1 Access Through Bridge Program
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program
WW International, Inc. said Weight Watchers Med+ will support Medicare beneficiaries seeking access to GLP-1 weight-loss medications through the Medicare GLP-1 Bridge Program.
The program, scheduled to run from July 1, 2026, through Dec. 31, 2027, allows eligible Medicare beneficiaries to purchase covered GLP-1 medications for weight loss for $50 per month. Weight Watchers said its Med+ program will help members determine eligibility, obtain prescriptions when clinically appropriate, and navigate insurance coverage, paperwork and prior authorization requirements.
The Medicare GLP-1 Bridge Program applies to eligible beneficiaries with Medicare Part D coverage who meet clinical requirements and have a prescription for an eligible GLP-1 medication. Weight Watchers said covered medications include Zepbound, KwikPen, Foundayo and Wegovy pen and pill. The medications are intended to be used alongside lifestyle interventions, including nutrition support and physical activity.
“For many people, weight loss is about health, mobility and being able to keep doing the things they love,” said Scott Honken, PharmD, chief commercial officer of Weight Watchers. “At Weight Watchers, our goal is to make the process feel less overwhelming by helping members understand their options, access care and receive a GLP-1 prescription if they’re eligible, while also providing the support they need to live well on treatment.”
Weight Watchers Med+ combines clinical care with behavioral support, including nutrition guidance, medication tracking, refill reminders and access to GLP-1 coaches through the company’s GLP-1 Success Program. The company said the program also includes strength-building guidance designed to help older adults preserve muscle mass and reduce the risk of frailty and falls during weight loss treatment.
Weight Watchers said its data show Med+ members prescribed a GLP-1 medication who regularly engaged with the GLP-1 Success Program lost 29.1 percent more body weight on average at 12 months than those who did not engage in behavioral support. The company also reported that 73 percent of Med+ members using the GLP-1 Success Program said Weight Watchers Med+ helped minimize medication side effects.
Weight Watchers said the program reflects its broader strategy of combining medication access, clinical oversight, digital tools and lifestyle support for people using GLP-1 therapies.
